Huadong Medicine Partners with Excientia, a UK-based AI Drug Discovery Company
publication date: Sep 10, 2020
Huadong Medicine formed a partnership with Exscientia, an AI drug discovery company in the UK, to discover novel small-molecule candidates for oncology. The initial project is focused on transcription control of DNA damage response genes. The approach will treat patients with defective DNA damage repair mechanisms, a condition that leads to high mutation frequency, in patients with ovarian and breast cancer. The partnership will advance Huadong's strategic goal of developing innovative medicines. More details....
Stock Symbol: (SHZ: 0963)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.